Semaglutide Marketing — Patient Acquisition for Medical Weight Loss Practices

Semaglutide has created the fastest-growing patient acquisition opportunity in medical aesthetics — and simultaneously one of the most legally and regulatorily complex marketing environments. Getting the strategy right means capturing a massive patient wave. Getting it wrong means regulatory action, ad account suspension, and wasted budget.

The patient demand is real and growing. Searches for 'semaglutide near me,' 'semaglutide [city],' and related terms have grown 300%+ since 2022. The challenge is that national telehealth platforms — Hims, Hers, Ro, Calibrate, and others — are spending aggressively to capture this search volume. CPCs for semaglutide keywords in major markets have risen substantially as competition increased.

The local practice advantage over telehealth is significant but must be communicated explicitly. In-person assessment identifies contraindications that remote providers miss. Physician-managed dose titration produces better outcomes than protocol-driven telehealth adjustments. Lab monitoring catches adverse events before they become serious. Patients who have tried telehealth semaglutide programs and struggled are the most receptive audience for local practice differentiation messaging.

Compounded semaglutide marketing requires specific compliance awareness. The FDA has been active in enforcement against misleading claims about compounded GLP-1 medications. Marketing that presents compounded semaglutide as bioequivalent to brand-name Ozempic or Wegovy makes claims that are not supported and have drawn regulatory attention. The compliant approach — and the one that actually converts best — is transparent education about what compounding is, why it exists, and why physician oversight of GLP-1 therapy matters regardless of medication source.